Fresenius SE & Co. KGaA (FSNUY) Stock Price & Analysis
Fresenius SE & Co. KGaA (FSNUY) — price $12.43 (0.00%), as of the Oct 6, 2026 trading session; market cap $28.0B.
Educational signal · not a buy or sell recommendation · How to read this
Fresenius SE & Co. KGaA · FSNUY · Healthcare · Medical - Care Facilities
Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products and services for dialysis, hospitals, and outpatient medical care.
Price as of Oct 6, 2026
Key Statistics
No publishable V2 score is available for this stock yet.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $12.43 | |
| Change on the day | 0.00% | |
| 52-week range | $10.33–$33.93 | |
| Market capitalisation | $28.0B | |
| Price / earnings (trailing) | 15.87 | |
| Beta (volatility vs the S&P 500) | 0.83 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Fresenius SE & Co. KGaA (FSNUY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Jul 13, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Jul 13, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Oct 6, 2026, except a card that shows its own read date.
Watch the FSNUY film — every key number, told as a short cinematic story
~2 min · open the film
What is Fresenius SE & Co. KGaA (FSNUY), and what does it report?
Short answer · as of
Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products and services for dialysis, hospitals, and outpatient medical care. Healthcare / Medical Care Facilities SEC filing business address: Else-Kroener Strasse 1, BAD Homburg, 2M, 61346. It employs 178,394 people and is led by Michael Sen. In Q2 FY2026 it reported revenue of $6.79B and net income of $436M. The market values it at $28.0B.
What do the latest results show for Fresenius SE & Co. KGaA (FSNUY)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $6.79B. Against analyst estimates the company has EPS beat 5 of 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $6.79B | $436M | $0.05 (diluted) |
| Q1 FY2026 | $6.64B | $496M | $0.06 (diluted) |
| Q4 FY2025 | $6.85B | $401M | $0.04 (diluted) |
| Q3 FY2025 | $6.14B | $385M | $0.04 (diluted) |
What are the financial strengths and risks for Fresenius SE & Co. KGaA (FSNUY)?
Short answer
The distress and quality screens read Altman Z 4.10 · Piotroski F 7. Trailing ratios: ROE 7.8% · ROA 3.5% · current ratio 1.27 · earnings yield 6.5% · free-cash-flow yield 6.4%.
What has been published about Fresenius SE & Co. KGaA (FSNUY)?
Fresenius SE & Co. KGaA Healthcare Stock: Key Questions Answered
Research dated 2026-09-12; the answers below are from that research, and the full attribution is under Sources. The last question is answered from this page's own dated data, not from the research.
How do Fresenius Helios and Fresenius Kabi shape the business?
Helios provides inpatient, outpatient and telemedicine care, while Kabi sells medicines, clinical nutrition and medical technologies. Fresenius therefore combines care delivery with healthcare products rather than relying on a single type of demand.
What is the FSNUY stock price today?
The last price recorded on this page for Fresenius SE & Co. KGaA (FSNUY) is $12.43, as of the Oct 6, 2026 trading session (source: Financial Modeling Prep (FMP) quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (18 figures)
The 18 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
id.hq | SEC filing business address | Else-Kroener Strasse 1, BAD Homburg, 2M, 61346 | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "Else-Kroener-Strasse 1, Bad Homburg vor der Höhe, HE, 61352, DE". |
FMP — 14 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $12.43 | FMP | Financial Modeling Prep (FMP) quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. | |
px.change | Change on the day | 0.00% | FMP | Financial Modeling Prep (FMP) quote | |
px.mcap | Market capitalization | $28.0B | FMP | Financial Modeling Prep (FMP) quote — Provider market cap uses the share class it prices; a company with more than one class may show a larger total elsewhere. Market cap record date: 2026-10-06. Source capture time was not supplied. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
id.business_summary | Business description (FMP excerpt) | Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products and services for dialysis, hospitals, and outpatient medical care. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | $0.00 | FMP | Financial Modeling Prep (FMP) quote | |
px.range52 | 52-week range | $10.33–$33.93 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 15.87 | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.83 | FMP | Financial Modeling Prep (FMP) company profile | |
id.sector | Sector / industry (provider taxonomy) | Healthcare / Medical Care Facilities | FMP | Financial Modeling Prep (FMP) company profile — The company's SEC filings classify it under SIC 3841 — Surgical & Medical Instruments & Apparatus. | |
id.employees | Employees | 178,394 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Michael Sen | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
fin.q_revenue | Revenue, Q2 FY2026 | $6.79B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2026 | $436M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 3 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 5 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-08-21 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 4.10 · Piotroski F 7 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-05 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 7.8% · ROA 3.5% · current ratio 1.27 · earnings yield 6.5% · free-cash-flow yield 6.4% | — | UNRECORDED | Stored key metrics — Date unknown |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-12
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products and services for dialysis, hospitals, and outpatient medical care. It operates through the following segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed. The Fresenius Medical Care segment caters to individuals with renal diseases. The Fresenius Kabi segment specializes in lifesaving medicines and technologies. The Fresenius Helios offers expertise in inpatient and outpatient care as well as in telemedicine. The Fresenius Vamed segment manages projects and services for hospitals and other healthcare facilities. The company was founded by Eduard Fresenius on October 1, 1912 and is headquartered in Bad Homburg, Germany. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
Data provided for informational purposes only.